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ABSTRACT Mesenchymal stem cells (MSCs) are multipotent cells and can differentiate into neurons and glial cells. In vitro
differentiation would be done by the addition of various factors. There remains no comparison for the differentiation of
MSCs from rat bone marrow (rBMMSCs) and adipose tissue (rATMSCS) into neurons and glial cells with basic fibroblast
growth factor (bFGF), epidermal growth factor (EGF), and brain‐derived neurotrophic factor (BDNF). The aims of this study
were to investigate the effect of bFGF, EGF, and BDNF supplementation on the differentiation ability of rBMMSCs and
rATMSCs into neurons and glial cells. MSCs were cultured with bFGF and EGF for 4 days and then BDNF was added until
day 8. Characterization of MSCs before and after induction was carried out by observing the cell morphology and several
cell markers. Flowcytometry analysis was performed for MSCs markers (CD90, CD29) and neurons and glial cell markers
(A2B5, Beta‐III‐tubulin, PSAN‐CAM); while MAP‐2, a neuron marker, was analyzed by immunocytochemistry. Induction of
both types of MSCs showed MAP‐2‐positive cells, decreased MSCs markers, and in rBMMSCs showed increased neuron
markers. The number of neuron marker positive cells in rBMMSCS was higher than rATMSCs. This study showed that
the addition of bFGF, EGF, and BDNF to the medium induced rBMMSCs into neurons and glial cells, but the conditions
were not optimal for rATMSC as judged by the expression of neural markers (A2B5, Beta‐III‐tubulin, PSAN‐CAM, andMAP‐2).
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1. Introduction
The Mesenchymal stem cells (MSCs) are undifferentiated
cells that have the ability of self­renewal and differenti­
ate into other cells (Dominici et al. 2006). MSCs are also
multipotent; MSCs are capable of proliferating and differ­
entiating into several constituent cells of the body such as
osteoblasts, chondrocytes, adipocytes, neurons, and glial
cells. The Mesenchymal stem cells (MSCs) can differen­
tiate into various cell types provides opportunities in cell
utilization as a therapy cell, especially in neurodegener­
ative diseases (Halim 2010). Neurons and glial cells de­
rived fromMSCswould offer an advantage for cell therapy
in the future for the regeneration of neurons and glial cells
in neurodegenerative diseases like spinal cord injury (Qu
and Zhang 2017).
The Mesenchymal stem cells (MSCs) can be obtained
from adult tissues such as bonemarrow, adipose tissue, pe­
ripheral blood, cord blood, tendons, and ligaments (Sand­
haanam et al. 2013). MSCs from the bone marrow can be
obtained in small amounts and are more invasive (Bagha­
ban Eslaminejad et al. 2008). MSCs from adipose tissue
are easily obtained in large quantities through liposuction
and easily propagated in vitro (Ikegame et al. 2011). MSCs
from bone marrow and adipose tissue are also able to dif­
ferentiate into osteoblasts, chondrocytes, adipocytes, neu­
rons, and glial cells (Safford et al. 2004; Rebelatto et al.
2008; Tohill et al. 2004).
Induction of MSCs differentiation into neurons and
glial cells can be done by adding various neurotrophic fac­
tors, growth factors, and chemicals in vitro. Several stud­
ies have reported that nerve growth factor (NGF), brain­
derived neurotrophic factor (BDNF), and neurotrophin­
3 (NT­3) are important neurotrophic factors in inducing
the proliferation and differentiation of neural stem cells
(Naghdi et al. 2009; Chen et al. 2014). In addition, sev­
eral growth factors such as epidermal growth factor (EGF),
basic fibroblast growth factor (bFGF), insulin­like growth
factor­1 (IGF­1), glial growth factor (GGF), and bonemor­
phogenetic protein­4 (BMP­4) supplementation to the cul­
ture medium can induce MSCs to neurons and glial cells
(Tohill et al. 2004; Liang et al. 2013; Guan et al. 2014).
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The MSCs differentiation into neurons and glial cells
in vitro can be characterized by the expression of neu­
rons and glial cells markers. A2B5 is an immature glial
marker in the brain area of the subventricular zone (SVZ)
that will develop into astrocytes and oligodendrocytes; and
it is widely expressed in embryonic and neonatal neural
networks (Dietrich et al. 2002; van Strien et al. 2014).
PSAN­CAM is a neuron progenitor cell or glial progen­
itor cell marker during brain development (neurogenesis)
(Zhang and Jiao 2015). PSAN­CAM is also reported to
be a marker of the development and migration of neurons
and synapse formation in the immature nervous system
(Quartu et al. 2008). Beta­III­tubulin (Tuj1) is a neuron
marker that begins to be expressed in the embryonic phase
of brain development and often found in post­mitotic neu­
rons that are still immature (und Halbach 2007). MAP­2
is a cytoskeletal protein needed for the proliferation, de­
velopment, differentiation, and maintenance of neurons
(Soltani et al. 2005; Liu et al. 2001).
Previous studies have reported the role of combina­
tions of several growth factors and neurotrophic factors
in differentiation into neurons and glial cells. MSCs se­
crete the growth factors and neurotrophic factor­like EGF,
bFGF, and BDNF in the conditioned medium (Wilkins
et al. 2009; Pawitan 2014). bFGF plays a role in cell
growth, differentiation, and survival (Yang et al. 2008).
EGF also plays a role in maintaining cell proliferation and
differentiation. The addition of both growth factors (EGF
and bFGF) into MSCs culture medium is also reported to
increase cell proliferation and support MSCs differentia­
tion into neurons and glial cells (Radtke et al. 2009; Hu
et al. 2013). BDNF plays a role in the differentiation, de­
velopment, survival of neuron stem cells, axon regener­
ation, and synapse formation (Lim et al. 2008). The ad­
dition of growth factors (bFGF, EGF, and BDNF) to the
culture medium can be used to induce MSCs differenti­
ation into neurons and glial cells. Nevertheless, the role
of these three factors in the differentiation of MSCs from
bone marrow and adipose tissue is unknown. Therefore,
this study aimed to investigate the effect of bFGF, EGF,
and BDNF supplementation on the differentiation ability
of rBMMSCs and rATMSCs into neurons and glial cells by
observing their markers (A2B5, Beta­III­tubulin, PSAN­
CAM, and MAP­2) to provide basic theoretical data for
further research.
2. Materials and Methods
The study was conducted at the Stem Cell Laboratory,
Centre for Research and Development of Biomedical and
Basic Health Technology (CRDBBHT), National Health
Research and Development Institute (NIHRD), Ministry
of Health of the Republic of Indonesia from March to Oc­
tober 2017.
2.1. Isolation and culture of rat MSCs from bone mar‐
row and adipose tissue
The male Sprague Dawley (SD) rats at age of 2­3
months and weighed 200­300 g were used in this study.
The animals were obtained from the Animal Laboratory,
CRDBBHT, NIHRD, Ministry of Health of the Republic
of Indonesia. The animals were handled in compliance
with the regulation of local animal welfare facility rules.
Isolation of rat adipose tissue and bone marrow from fe­
mur and tibia bones were performed under anesthesia with
ketamine (75­100 mg/kg) in mixture with xylazine (5­10
mg/kg) via intraperitoneal injection. This procedure has
been approved by the ethical committee of NIHRD.
Isolation of MSCs from the femur and tibia bones of
rat (rat bone marrow MSCs, rBMMSCs) was done by
cutting off each bone and flushing modification methods
by a modified method of Rinendyaputri and Noviantari
(2015), by flushing the bones with a syringe of MEM cul­
ture medium (Sigma) supplemented with 10% fetal bovine
serum (FBS) (Gibco), sodium bicarbonate (Sigma), non­
essential amino acids 1% (Sigma), mercaptoethanol 0.1
mM (Sigma), and gentamicin (Sigma). The cells were in­
cubated in a 5% CO2 incubator (Heracell Vios 160i) at 37
°C. The culture mediumwas replaced after MSCs attached
in 2­3 d (Rinendyaputri and Noviantari 2015).
Isolation of MSCs from rat adipose tissue (rATMSCs)
was done by washing the adipose tissue in phosphate­
buffered saline (PBS) supplemented with 1% gentamicin
in a petri dish. Adipose tissue was chopped into pieces
(±2­3 mm2) using sterile scissors and inserted into a con­
ical tube containing a 0.075% type I collagenase solution
(Gibco) with a ratio of 1:2 of adipose tissue to collage­
nase solution. The mixture was incubated in a water bath
at 37 °C for 1 h with shaking every 5 min. After incuba­
tion, the mixture was centrifuged at 1400 rpm for 10 min,
then the supernatant was removed, and PBS was added
to the pellet. The suspension was filtered with a 70 µm
cell strainer (or electroplated tea filters). The filtered cell
suspension was centrifuged again at 1400 rpm for 10 min
and the supernatant was removed. The pellets were resus­
pended with a culture medium (MEM supplemented with
10% FBS, sodium bicarbonate, 1% non­essential amino
acids, 0.1 mM mercaptoethanol, gentamicin, and Gluta­
MAX [Gibco]). MSCs from adipose tissue were cultured
in an incubator with 5% CO2 at 37 °C. The medium was
replaced every 2­3 d. Cells that have been confluent 80%
are ready to passage.
When MSCs were nearly confluent (70­80%), the
cells were passaged with trypsin­EDTA (Gibco). The
mediumwas removed. Cells werewashed twicewith PBS.
Trypsin­EDTA was added to the cells, and the cells were
incubated for 5 min at 37 °C. The cells were suspended
in the culture medium. The number of cells was counted
with a Neubauer hemacytometer cell counting chamber af­
ter trypan blue staining. The cells were replated in a 12­
well plate (1×105 cells per well), and cells were incubated
at 37 °C in the culture medium. The medium was replaced
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FIGURE 1Morphology of MSCs before and after induction. (a‐b) Morphology of rBMMSCs (a) and rATMSCs (b) after 5 d of primary culture
were depicted before induction. Cells were isolated from 3‐month‐old rats. (c‐d) Morphology of rBMMSCs (c) and rATMSCs (d) 8 d after
induction with bFGF, EGF, and BDNF. Blue arrows indicate neuron‐like cells. (e‐f) Expression of MAP‐2 as a mature neuron marker (red
arrows) after induction. Representative pictures after MAP‐2 staining in rBMMSCs (e) and rATMSCs (f) are shown. Negative control (g) and
positive control (h) are shown. The brown cells indicate MAP‐2‐positive cells.
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every 2­3 d.
2.2. Induction of MSCs neural differentiation with
bFGF, EGF, and BDNF
Induction methods of MSCs neural differentiation were
modified from Anghileri et al. (2008) by changing
Dulbecco’s modified Eagle’s medium with Neurobasal
medium, omitting retinoic acid (RA) to induce MSCs, and
omitting the isolation of spherical floating aggregates af­
ter incubation with bFGF and EGF. The MSCs at the pas­
sage (P3) were harvested by trypsinization and then were
centrifuged. The pellet was resuspended in the induction
medium on a 12­well plate (in duplicate). The induc­
tion consisted of 2 stages: (1) the cells were cultured in
Neurobasal medium supplemented with bFGF and EGF
(20 ng/mL) containing 10% FBS, 2% B27 supplement
(Gibco), antibiotic and antimycotic, and GlutaMAX for
4 d; (2) the cells were cultured with the same medium
as (1) with the addition of BDNF (20 ng/mL) until day
8. The cells were incubated in a 5% CO2 incubator at
37 °C. The induction medium was replaced every 2­3 d.
Induced MSCs were observed under an inverted micro­
scope (Nikon ECLIPSE TE2000­U) with NIS­Elements
F Imaging Software. Flowcytometry analysis of A2B5,
beta­III­tubulin, and PSA­NAM; and immunocytochem­
istry of MAP­2 were conducted on day 8.
2.3. Flowcytometry
In this study, rBMMSCs and rATMSCS were character­
ized with CD29+, CD90+, and CD45­ (Biolegend). In­
duced MSCs were characterized by using A2B5­, PSAN­
CAM+ (Miltenyi Biotec), and Beta­III­tubulin (Biole­
gend) markers according to the instruction kit. The flow­
cytometry analysis was performed by using a BD Accuri
C6 Plus. Flowcytometry data analyzed with Flowjo V10:
population gated by total MSC, the single cells; and the
markers of MSCs, neurons, and glial cells. The control
population was stained with isotype antibodies. Gates
were drawn based on matched isotype control cocktails.
2.4. MAP‐2 immunocytochemistry of induced MSCs
Immunocytochemistry of neural differentiation­induced
MSCs was adopted from Stephanie et al. (2013) by de­
creasing the incubation time. The medium was discarded
from the well then washed with PBS twice. Fixation was
done by incubating induced MSCs in 4% paraformalde­
hyde (PFA) for 15 min, then washed with PBS three
times each for 5 min. Blocking steps were performed by
blocking endogenous peroxidase with 3% (v/v) H2O2 in
methanol (MerckK38122297) for 15min, and by blocking
nonspecific backgrounds with background snipper (Starr
Trek Universal HRP Detection Kit Biocare) for 15 min.
Cells were washed in PBS three times each for 5 min.
Then, cells were incubated with MAP­2 primary antibody
(Santa Cruz sc­74421) at 4 °C overnight and washed in
PBS three times each for 5 min. Cells were incubated
with secondary HRP­conjugated antibody (Trekkie Uni­
versal Link, Starr Trek Universal HRP Detection Kit Bio­
care®) for 15 min, then cells were washed in PBS for 5
min. After that, cells were incubated with Trek­Avidin­
HRP (Starr Trek Universal HRP Detection Kit Biocare)
for 15 min, followed by washing in PBS for 5 min. Chro­
mogen substrate diamino­benzidine (DAB) dissolved in
substrate buffer (Starr Trek Universal HRP Detection Kit
Biocare) were added and incubated for 1­2 min, then cells
were washed with ultrapure water (Milli­Q, Merck), water
for 10 min. Cells were counterstained with Hematoxylin
Mayer (Biocare 3570) for 1­2 min and washed in ultrapure
water for 5 min.
Positive and negative controls were included in every
staining protocol. Positive control for MAP­2 immuno­
cytochemistry was primary neuron culture from rat brain.
MAP­2­positive cells were indicated by brown color in the
cytoplasmic and nucleus area. The negative control was
obtained by omitting MAP­2 primary antibody.
2.5. Data analysis
Data on percentage of MSCs, neuron, and glial marker
positive and negative were analyzed using Statistical Prod­
uct and Service Solution (SPSS) 16. A comparison be­
tween groups was performed using a t­test with a 95% con­
fidence level (P<0.05).
3. Results and Discussion
Isolated MSCs from bone marrow and adipose tissue
showed morphology dominated by cells such as fibrob­
last cells, then cells became confluent andmonolayer (Fig­
ure 1A and 1B). Immunophenotype analysis of rBMMSCs
and rATMSCs at passage 3 (P3) before and after induc­
tion using flowcytometry showed that more than 50% of
cells were CD29+ and CD90+ (MSCs markers) and less
than 3% cells were CD45+ (hematopoietic marker) (Fig­
ure 2A). After differentiation induction, the percentages
of CD90, and CD29 positive were decreased. Decreases
in the percentage of rBMMSCsmarkers (CD29 andCD90)
positive cells before and after induction were as 1.95­, and
1.18­ fold, respectively. The decrease in the percentage
of rATMSCs markers (CD29) before and after induction
was as 1.66­ fold, while the percentage of CD90­positive
cells in rATMSCs was slightly increased. The comparison
between the percentage of CD29 of both MSCs showed
a significant difference. Based on the paired sample t­
test, CD29 had a significant difference with the p­value
of 0.007 for rBMMSCs and 0.004 for rATMSCs before
and after induction. Comparison between rBMMSCs and
rATMSCs after induction showed that CD29 was signifi­
cantly different (P<0.05).
Induced MSCs showed morphology change after in­
duction with bFGF, EGF, and BDNF. Both MSCs showed
characteristics of neuron­like morphology with a con­
densed nucleus, contracted cytoplasm (blue arrow) with
two or three cellular processus like bipolar neurons and
multipolar neurons (Figures 1C and 1D). MAP­2 expres­
sion in induced MSCs was observed on day 8 after the ad­
dition of bFGF, EGF, and BDNF. MAP­2 positive cells
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FIGURE 2 Characterization of MSCs before and after neuron induction. (a) Comparison of expression of CD45, CD29, and CD90 between
rBMMSCs and rATMSCs before and after differentiation induction. The percentage of CD45 and CD29 from rBMMSCs and CD45 from
rATMSCs showed a significant difference before and after induction (n=3, three independent experiments in duplicate measurement for each
experiment). Percentage of CD29 and CD90 after induction between rBMMSCs and rATMSCs showed a significant difference (n=3, three
independent induction experiments in duplicate measurement for each experiment). *P<0.05. (b‐e) Representative figures of flowcytometry
analysis. Immunophenotype of MSCs marker of rBMMSCs before induction (b) and after induction (c). Immunophenotype of MSCs of
rATMSCs before induction (d) and after induction (e). Each panel consists of (1) isotype control and (2) sample.
showed brown color in the cytoplasmic and nucleus area
(red arrow) (Figure 1E and 1F). MAP­2­negative cells ap­
peared as cells with bluish staining nucleus or hematoxylin
stained nucleus (Figure 1G).
After induction with bFGF, EGF, and BDNF, rB­
MMSCs showed an increased percentage of positive cells
for the glial progenitor maker, A3B5, and the immature
neuron markers, beta­III­tubulin, and PSAN­CAM. In­
creases in the percentage of neuron markers A2B5­, beta­
III­tubulin­, and PSAN­CAM­positive cells before and af­
ter induction of rBMMSCs were as 1.34­, 1.53­, and 1.47­
fold, respectively. But, rATMSCs show decreases in the
percentage of neuron markers A2B5, beta­III­tubulin, and
PSAN­CAM before and after induction of rATMSCs were
as 1.66­, 1.2­, and 2.03­fold, respectively (Figure 3A). Us­
ing a paired t­test, the comparison between the percentage
of A2B5 of rBMMSCs before and after induction showed
a significant difference. The percentage of A2B5 from rB­
MMSCs had a significant difference with p­value of 0.032.
3.1. Discussion
Isolation and culture of rat bone marrow and rat adipose
tissue MSCs were successfully performed, and isolated
MSCs showed a high percentage of MSCs markers (CD90
and CD29) with a low percentage of hematopoietic sur­
face markers (CD45). These results are consistent with the
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FIGURE 3 Characterization of neurons and glial cells. (a) Comparison of expression of PSA‐NCAM, A2B5, and Beta‐III‐tubulin in rBMM‐
SCs and rATMSCs before and after differentiation induction. Percentage of A2B5 and Beta‐III‐tubulin from rBMMSCs, PSA‐NCAM, and
Beta‐III‐tubulin from rATMSCs showed a significant difference before and after induction (n=3, three independent experiments in duplicate
measurement for each experiment). P<0.05. (b‐e) Representative figures of flowcytometry analysis. Immunophenotype of neurons and glial
cells marker of rBMMSCs before (b) and after induction (c). Immunophenotype of neurons and glial cells marker of rATMSCs before (d) and
after induction (e). Each panel consists of (1) isotype control and (2) sample.
MSCs criteria based on the International Society for Cel­
lular Therapy (ISCT), which defines MSCs as cells able
to attach to a plastic culture container, positive for CD90,
CD73, CD105, and CD44, and negative for CD34, CD45,
HLA­DR, and CD11b.1.
In this research, we usedMSCs at passage 3 because in
this passage, cells show high proliferation and high mul­
tilineage differentiation capacity. The proliferation of the
cells as determined by the cumulative population doubling
level was observed at its peak on passage 3, and the pro­
liferation stopped after passage 5 (Lee et al. 2013).
From our research, we have confirmed that rATMSCs
and rBMMSCs express neuron markers spontaneously be­
fore induction. Deng et al. (2006) reported that although
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in the absence of specialized induction reagents, MSCs
spontaneously express certain neuron phenotype markers.
MSCs are positive for several neuron­specific proteins, in­
cluding β­III tubulin (12%) and NFM (13.2%); negative
for PSA­NCAM, a surface protein expressed on migra­
tory neuroblasts; positive for the astrocyte­specific pro­
tein, S100­β (15%); but negative for the astrocyte interme­
diate filament proteins, GFAP, and vimentin (Deng et al.
2006).
In this study, retinoic acid (RA) was removed from the
neural differentiation induction medium of Anghileri et al.
(2008) because we wanted to know the role of the three
growth factors (EGF, bFGF, and BDNF) exclusively in the
differentiation of MSCs into neurons and glial cells to pro­
vide basic theoretical data for further research. Anghileri
et al. (2008) used 30 d for induction and obtained neuron
differentiation in 57% of ATMSC. In this study, we in­
duced MSCs with only 3 growth factors (bFGF, EFG, and
BDNF) for 8 d, and obtained 15% of cells differentiated
into neurons and glial cells. This efficiency is comparable
to those reported previously. Jeon et al. (2007) reported
that MSCs cultured in neuron pre­induction medium con­
taining a combination of growth factors NT­3 (30 ng/mL)
and bFGF (10 ng/mL) for 4­5 d followed by an induc­
tion medium containing NT­ 3 (30 ng/mL) and BDNF (10
ng/mL) for 7 d produces Nestin­positive cells (4.7 ± 0.8%
pre­induction and 14.2 ± 2.0% post­induction).
In the present research, we omitted the isolation of
spherical floating aggregates (neurosphere) after incuba­
tion with bFGF and EGF to make an easy and more effi­
cient differentiation protocol. There are several studies of
differentiation MSCs to neurons without neurosphere iso­
lation steps. Guan et al. (2014) reported that rat MSCs
from bone marrow differentiated to neurons by adding
combinations of growth factors (EGF, bFGF, IGF­1, and
NT­3) without neurosphere isolation (Guan et al. 2014).
Ikegame et al. (2011) also reported that mice MSCs from
bone marrow and adipose tissue differentiated to neurons
and glial cells after 48 h with several chemical compounds
without neurosphere isolation. The percentage of neu­
ron marker from MSCs from adipose tissue was 40±6%
(MAP­2), 14±2% (NeuN), and 23±5% (Nestin) (Ikegame
et al. 2011).
In the differentiation of MSCs into neurons and glial,
there are a variety of different markers according to the
stages of differentiation (Rushing and Ihrie 2016). PSA­
NCAMandA2B5 aremarkers of neurogenesis as amarker
of an immature neuron and glial cells. This is in accor­
dance with the previous research conducted by Czarnecka
et al. (2017), which states that MSCs from the human um­
bilical cord can differentiate into neurons and glial cells us­
ing commercial neuron mediums (MSC Neurogenic Dif­
ferentiation Medium) which produces NCAM+ (50,83 ±
3.01%) and A2B5+ (19.97 ± 1.70%). In this study, a de­
crease in the percentage of neuron and glial markers may
be due to the differentiation of MSCs that are already in
the mature neuron stage with positive MAP­2 markers.
Our current result differs from that of Ikegame et al.
(2011), in which MSCs from adipose tissue showed a bet­
ter efficacy in treating ischemic stroke in mice by injecting
MSCs from adipose tissue or bone marrow. They reported
that several tissue regenerative factors like vascular en­
dothelial cell growth factor (VEGF), angiopoietin­1, and
hepatocyte growth factor (HGF) frommouse ATMSCs are
higher than BMMSCs Ikegame et al. (2011). Assessment
of secreted growth factors from rBMMSCs and rATMSCS
should be done to compare concentrations of growth and
neurotrophic factors in the conditioned medium of both
MSCs. Further, add more growth factors and characteri­
zation of neurons and glial cells induced from rBMMSCs
and rATMSCS should also be done with another neural
markers, i.e,. Nestin, NeuN, and GFAP.
4. Conclusions
The addition of bFGF, EGF, and BDNF to the medium
induces rBMMSCs into neurons and glial cells, but the
medium induction is not optimal for rATMSC by the
expression of neural markers (A2B5, Beta­III­tubulin,
PSAN­CAM, and MAP­2) and needs to be improved.
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